Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
P61812
UPID:
TGFB2_HUMAN
Alternative names:
Cetermin; Glioblastoma-derived T-cell suppressor factor
Alternative UPACC:
P61812; B4DKC5; P08112; Q15579; Q15581; Q4VAV9
Background:
Transforming growth factor beta-2 proprotein, also known as Cetermin and Glioblastoma-derived T-cell suppressor factor, plays a pivotal role in various biological processes including angiogenesis and heart development. It is a precursor of the Latency-associated peptide (LAP) and Transforming growth factor beta-2 (TGF-beta-2) chains, essential for maintaining TGF-beta-2 in a latent state within the extracellular matrix.
Therapeutic significance:
Linked to Loeys-Dietz syndrome 4, characterized by arterial tortuosity and aortic dissection among other symptoms, this protein's gene variants highlight its critical role in disease manifestation. Understanding the role of Transforming growth factor beta-2 proprotein could open doors to potential therapeutic strategies for this syndrome.